Qualigen Therapeutics (QLGN) Competitors

Qualigen Therapeutics logo
$0.41 0.00 (-0.63%)
As of 11/19/2026

QLGN vs. MBAI, BNZI, TAOP, AUUD, and IPST

Should you buy Qualigen Therapeutics stock or one of its competitors? Qualigen Therapeutics's main competitors and comparable companies include MBody AI (MBAI), Banzai International (BNZI), Taoping (TAOP), Auddia (AUUD), and Heritage Distilling (IPST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Qualigen Therapeutics compare to MBody AI?

MBody AI (NASDAQ:MBAI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

1.1% of MBody AI shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 0.5% of MBody AI shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MBody AI is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBody AIN/AN/A$4.14M-$7.42N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

MBody AI presently has a consensus target price of $10.00, indicating a potential upside of 392.61%. Given MBody AI's stronger consensus rating and higher probable upside, equities analysts plainly believe MBody AI is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBody AI
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, MBody AI had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for MBody AI and 0 mentions for Qualigen Therapeutics. MBody AI's average media sentiment score of 0.37 beat Qualigen Therapeutics' score of 0.00 indicating that MBody AI is being referred to more favorably in the media.

Company Overall Sentiment
MBody AI Neutral
Qualigen Therapeutics Neutral

MBody AI has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
MBody AIN/A N/A N/A
Qualigen Therapeutics N/A N/A -202.16%

Summary

MBody AI beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Banzai International?

Qualigen Therapeutics (NASDAQ:QLGN) and Banzai International (NASDAQ:BNZI) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Qualigen Therapeutics has higher earnings, but lower revenue than Banzai International. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Banzai International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Banzai International$11.48M0.24-$22.49M-$110.47N/A

In the previous week, Banzai International had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Banzai International and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Banzai International'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Banzai International Neutral

Qualigen Therapeutics has a net margin of 0.00% compared to Banzai International's net margin of -237.54%. Qualigen Therapeutics' return on equity of 0.00% beat Banzai International's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Banzai International -237.54%-391.73%-74.14%

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Banzai International has a beta of -1, suggesting that its share price is 200% less volatile than the broader market.

Banzai International has a consensus target price of $42.00, indicating a potential upside of 2,098.95%. Given Banzai International's stronger consensus rating and higher possible upside, analysts plainly believe Banzai International is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Banzai International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Banzai International shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 2.8% of Banzai International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Banzai International beats Qualigen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Taoping?

Qualigen Therapeutics (NASDAQ:QLGN) and Taoping (NASDAQ:TAOP) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Taoping
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Taoping has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Qualigen Therapeutics has higher earnings, but lower revenue than Taoping.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Taoping$30.82M0.07-$10.06MN/AN/A

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 4.0% of Taoping shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 45.4% of Taoping shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Taoping'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Taoping Neutral

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Taoping N/A N/A N/A

Summary

Taoping beats Qualigen Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Auddia?

Qualigen Therapeutics (NASDAQ:QLGN) and Auddia (NASDAQ:AUUD) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Qualigen Therapeutics' return on equity of 0.00% beat Auddia's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Auddia N/A -142.08%-127.55%

3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 1.6% of Auddia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Auddia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
AuddiaN/AN/A-$7.69M-$6.16N/A

Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Auddia has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Auddia
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Auddia had 6 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Auddia and 0 mentions for Qualigen Therapeutics. Auddia's average media sentiment score of 0.71 beat Qualigen Therapeutics' score of 0.00 indicating that Auddia is being referred to more favorably in the news media.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Auddia Positive

Summary

Auddia beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Heritage Distilling?

Heritage Distilling (NASDAQ:IPST) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

3.2% of Qualigen Therapeutics shares are held by institutional investors. 3.7% of Heritage Distilling shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Qualigen Therapeutics has a net margin of 0.00% compared to Heritage Distilling's net margin of -2,064.21%. Qualigen Therapeutics' return on equity of 0.00% beat Heritage Distilling's return on equity.

Company Net Margins Return on Equity Return on Assets
Heritage Distilling-2,064.21% -239.27% -205.21%
Qualigen Therapeutics N/A N/A -202.16%

Heritage Distilling has a beta of 5.32, indicating that its stock price is 432% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Heritage Distilling currently has a consensus price target of $164.00, indicating a potential upside of 10,640.01%. Given Heritage Distilling's stronger consensus rating and higher possible upside, analysts clearly believe Heritage Distilling is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heritage Distilling
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Qualigen Therapeutics has lower revenue, but higher earnings than Heritage Distilling. Heritage Distilling is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heritage Distilling$10.12M0.15-$137.71M-$17.08N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

In the previous week, Heritage Distilling had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Heritage Distilling and 0 mentions for Qualigen Therapeutics. Heritage Distilling's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
Heritage Distilling Neutral
Qualigen Therapeutics Neutral

Summary

Heritage Distilling and Qualigen Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QLGN vs. The Competition

MetricQualigen TherapeuticsSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$692K$14.75B$24.33B$11.20B
Dividend YieldN/A3.41%2.99%4.74%
P/E Ratio-0.0546.7741.9929.11
Price / SalesN/A6.145.345.36
Price / CashN/A27.1726.3621.66
Price / Book-0.105.774.813.58
Net Income-$6.26M$426.50M$794.18M$393.99M
7 Day Performance-51.43%-6.38%-7.60%-7.09%
1 Month Performance-61.87%-9.16%-11.81%-10.32%
1 Year Performance-85.83%-9.82%0.44%-8.04%

Qualigen Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QLGN
Qualigen Therapeutics
N/A$0.41
-0.6%
N/A-87.2%$692KN/AN/A50
MBAI
MBody AI
3.2532 of 5 stars
$2.12
+3.4%
$10.00
+371.7%
N/A$2.82MN/AN/A85
BNZI
Banzai International
1.5399 of 5 stars
$1.91
flat
$42.00
+2,099.0%
N/A$2.78M$11.48MN/A33
TAOP
Taoping
0.7763 of 5 stars
$0.26
+5.1%
N/A-88.4%$2.48M$25.09MN/A118
AUUD
Auddia
1.037 of 5 stars
$0.31
-3.5%
N/A-97.7%$2.20M$7.58KN/A5

Related Companies and Tools


This page (NASDAQ:QLGN) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners